Biologics and Conjugates CDMO Services
As a subsidiary of Porton Pharma Solutions, a globally recognized CDMO, Porton Biologics and Conjugates CDMO Platform offers comprehensive, one-stop drug development and manufacturing services for biologics and conjugates, including ADCs, AOCs, PDCs, and more.
150+
Scientists
50+
Projects (IND/P1/P2/P3/NDA)
40+
Customers
Our Services
Conjugates
-
ADC
Antibody-Drug Conjugate -
AOC
-
PDC
-
PRC
-
SMDC
Targeting-vehicle
Antibody
Peptide
Small Molecule
Linker
Cys (-SH): S-S, Maleimide Group (mc, mcc, etc.)
Lys (-NH2): Activated Acid(CO-OSu, etc.)
Short Peptide (VC, GFGG, etc.)
PEG
Click Chemistry
pH-Sensitivity (HN-CH2-O-, C+N-NH=CO-, Hydrazine, Carbonate)
Multi Branches
Payload
Cytotoxic Drugs
Oligonucleotides
Radionuclides
Fluorescers
Early Stage Development
mg ~ g Scale Library
Developability Assessment
Process Development
Payload-Linker Process Development
Targeting-vehicle Process Development
Bioconjugation and Purification Process Development
DP Formulation & Process Development
Manufacturing
Payload-Linker Manufacturing
Targeting-vehicle Manufacturing
DS Manufacturing
DP Manufacturing
Anynitical Development and QC
Analytical Method Development & Validation
Release Testing
Stability Study
Registration Services
CMC Filing Dossier
Supporting and Communication During Filing Process
-
ADC
Antibody-Drug Conjugate
-
AOC
-
PDC
-
PRC
-
SMDC
Antibody
Peptide
Small Molecule
Cys (-SH): S-S, Maleimide Group (mc, mcc, etc.)
Lys (-NH2): Activated Acid(CO-OSu, etc.)
Short Peptide (VC, GFGG, etc.)
PEG
Click Chemistry
pH-Sensitivity (HN-CH2-O-, C+N-NH=CO-, Hydrazine, Carbonate)
Multi Branches
Cytotoxic Drugs
Oligonucleotides
Radionuclides
Fluorescers
mg ~ g Scale Library
Developability Assessment
Payload-Linker Process Development
Targeting-vehicle Process Development
Bioconjugation and Purification Process Development
DP Formulation & Process Development
Payload-Linker Manufacturing
Targeting-vehicle Manufacturing
DS Manufacturing
DP Manufacturing
Analytical Method Development & Validation
Release Testing
Stability Study
CMC Filing Dossier
Supporting and Communication During Filing Process
Sites
Minhang, Shanghai
- OEB 4 &5
- 50 L
- Pre-clinical to Tox Batch
Fengxian, Shanghai
- OEB 4 & 5
- 200 L
- Phase I to Commercial
Waigaoqiao, Shanghai
- Antibody (200L-500L)
- Bioconjugation (10-200L, OEB 5)
- Phase I to Phase II
New Jersey, Cranbury
- Payload-Linker (10-100 L, OEB 4 & 5)
- Bioconjugation (200-500L, OEB 5)
- Pre-clinical to Commercial
News
MoreNews2024-10-24
Porton Pharma Solutions Signed Strategic Partnership with Shanghai InnoStar
More
News2024-10-14
Driving innovation and excellence in the CDMO industry, Porton Pharma Solutions 2024 CPHI Europe Review
More
News2024-10-10
Connect with Porton J-STAR at AAPS PharmSci 360 2024 @ Booth 2431
More
News2024-09-30
Technical Enability | Porton’s Team of Global Chemical Engineering and Technology Published Breakthrough Results in Crystal Growth & Design and reported them at the 2024 Crystal Engineering Gordon Research Conference
More
News2024-09-19
Presenter Profile Reveal, Meeting Your CDMO Experts In Booth 5C17
More
